| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $14,889,223 | 19 | 100 |
| RYAN ARTHUR F | director | 0 | $0 | 5 | $434,683 | $-434,683 |
| Guarini Kathryn | director | 0 | $0 | 3 | $1.02M | $-1.02M |
| BROWN MICHAEL S | director | 0 | $0 | 1 | $1.69M | $-1.69M |
| Bassler Bonnie L | director | 0 | $0 | 2 | $1.77M | $-1.77M |
| Pitofsky Jason | VP Controller | 0 | $0 | 2 | $1.87M | $-1.87M |
| Zoghbi Huda Y | director | 0 | $0 | 2 | $1.92M | $-1.92M |
| McCourt Marion | EVP Commercial | 0 | $0 | 3 | $2.99M | $-2.99M |
| MURPHY ANDREW J | Co-Chief Scientific Officer | 0 | $0 | 1 | $3.2M | $-3.2M |
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are …
Over the last 12 months, insiders at Regeneron Pharmaceuticals, Inc. have bought $0 and sold $14.89M worth of Regeneron Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Regeneron Pharmaceuticals, Inc. have bought $0 and sold $102.35M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 105,820 shares for transaction amount of $51.01M was made by Sanofi (10 percent owner) on 2017‑08‑24.
| 2026-10-30 | Sale | McCourt Marion | EVP Commercial | 1,132 0.001% | $869.43 | $984,195 | ||
| 2026-10-30 | Sale | BROWN MICHAEL S | director | 1,929 0.0018% | $875.00 | $1.69M | ||
| 2026-10-30 | Sale | Guarini Kathryn | director | 400 0.0004% | $900.00 | $360,000 | ||
| 2026-10-14 | Sale | MURPHY ANDREW J | Co-Chief Scientific Officer | 4,147 0.004% | $772.70 | $3.2M | +4.13% | |
| 2026-09-03 | Sale | McCourt Marion | EVP Commercial | 1,131 0.0011% | $857.39 | $969,708 | -6.10% | |
| 2026-09-02 | Sale | McCourt Marion | EVP Commercial | 1,215 0.0012% | $850.00 | $1.03M | -6.90% | |
| 2026-09-02 | Sale | Guarini Kathryn | director | 400 0.0004% | $850.00 | $340,000 | -6.90% | |
| 2026-08-10 | Sale | Zoghbi Huda Y | director | 800 0.0008% | $800.00 | $640,000 | -0.83% | |
| 2026-08-10 | Sale | Guarini Kathryn | director | 400 0.0004% | $800.00 | $320,000 | -0.83% | |
| 2026-07-02 | Sale | RYAN ARTHUR F | director | 200 0.0002% | $650.15 | $130,030 | +20.34% | |
| 2026-05-01 | Sale | RYAN ARTHUR F | director | 100 <0.0001% | $705.24 | $70,524 | +5.51% | |
| 2026-04-01 | Sale | RYAN ARTHUR F | director | 100 <0.0001% | $777.27 | $77,727 | -3.94% | |
| 2026-03-02 | Sale | RYAN ARTHUR F | director | 100 <0.0001% | $785.50 | $78,550 | -5.30% | |
| 2026-02-19 | Sale | Zoghbi Huda Y | director | 1,638 0.0016% | $781.33 | $1.28M | -4.02% | |
| 2026-02-09 | Sale | RYAN ARTHUR F | director | 100 <0.0001% | $778.53 | $77,853 | -3.26% | |
| 2026-02-09 | Sale | Pitofsky Jason | SVP Controller | 2,036 0.002% | $778.52 | $1.59M | -3.26% | |
| 2026-01-07 | Sale | Bassler Bonnie L | director | 1,500 0.0015% | $800.00 | $1.2M | -7.05% | |
| 2025-11-20 | Sale | Bassler Bonnie L | director | 760 0.0007% | $750.00 | $570,000 | +2.49% | |
| 2025-11-07 | Sale | Pitofsky Jason | VP Controller | 431 0.0004% | $651.43 | $280,766 | +14.84% | |
| 2025-10-29 | Sale | POON CHRISTINE A | director | 6,500 0.0071% | $654.27 | $4.25M | +15.24% |
| RYAN ARTHUR F | director | 17303 0.0168% | $16.84M | 1 | 65 | +15.02% |
| Sanofi | 10 percent owner | 279766 0.2718% | $272.31M | 53 | 7 | +15.98% |
| SING GEORGE L | director | 26349 0.0256% | $25.65M | 2 | 49 | +19.34% |
| POON CHRISTINE A | director | 2352 0.0023% | $2.29M | 2 | 7 | +28.16% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
Regeneron Pharmaceuticals, Inc. (REGN) | $2,449,191,716 | 58 | 16.50% | $100.2B |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 781 | +58.07% | 9M | +10.04% |
| Decreased Positions | 589 | -43.79% | 8M | -8.76% |
| New Positions | 263 | New | 983,105 | New |
| Sold Out Positions | 121 | Sold Out | 2M | Sold Out |
| Total Postitions | 1,537 | +14.28% | 89M | +1.28% |
| Vanguard Group Inc | $7.02M | 8.79% | 9.05M | -375,779 | -3.99% | 2025-09-30 |
| Blackrock, Inc. | $6.86M | 8.58% | 8.84M | -438,911 | -4.73% | 2025-09-30 |
| State Street Corp | $3.64M | 4.56% | 4.69M | -140,779 | -2.91% | 2025-09-30 |
| Dodge & Cox | $3.53M | 4.42% | 4.55M | +724,562 | +18.94% | 2025-09-30 |
| Jpmorgan Chase & Co | $3.16M | 3.95% | 4.07M | +132,708 | +3.37% | 2025-09-30 |
| Geode Capital Management, Llc | $1.97M | 2.46% | 2.54M | +70,844 | +2.87% | 2025-09-30 |
| Franklin Resources Inc | $1.9M | 2.38% | 2.45M | +139,647 | +6.04% | 2025-09-30 |
| Capital World Investors | $1.55M | 1.94% | 2M | +32,348 | +1.65% | 2025-09-30 |
| Loomis Sayles & Co L P | $1.54M | 1.92% | 1.98M | +38,383 | +1.98% | 2025-09-30 |
| Fmr Llc | $1.5M | 1.88% | 1.94M | -1M | -41.81% | 2025-09-30 |